The pandemic has certainly provided new challenges and opportunities in the management of acute ischemic stroke (AIS); however, data regarding outcomes of intravenous tissue plasminogen activator (IV TPA) administration in stroke patients with COVID-19 remains limited.<h4>Case presentation</h4>Three AIS patients with confirmed COVID-19 treated using IV tPA. The gene discussed is PLAT; the disease is stroke disorder.